Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Creo Medical ( (GB:CREO) ) has shared an announcement.
Creo Medical Group plc has announced a change in its Nominated Adviser and Broker from Numis Securities Limited to Deutsche Bank AG, London Branch, following the acquisition of Numis’s parent company by Deutsche Bank. This change is expected to support Creo’s strategic operations and potentially enhance its market positioning by aligning with a globally recognized financial institution.
Spark’s Take on GB:CREO Stock
According to Spark, TipRanks’ AI Analyst, GB:CREO is a Neutral.
Creo Medical’s overall stock score is primarily impacted by its weak financial performance, characterized by declining revenues and persistent losses. However, positive corporate events and neutral technical indicators provide some offset, suggesting potential for future improvement if financial challenges are addressed.
To see Spark’s full report on GB:CREO stock, click here.
More about Creo Medical
Creo Medical Group plc is a medical device company specializing in minimally invasive electrosurgical devices aimed at enhancing endoscopic procedures for pre-cancer and cancer patients. The company focuses on improving patient outcomes through its advanced CROMA technology powered by Kamaptive, which integrates multi-modal energy sources for precise and controlled surgical solutions. This technology is designed to offer safer, less invasive, and cost-efficient surgical options.
Average Trading Volume: 1,893,630
Technical Sentiment Signal: Sell
Current Market Cap: £55.17M
See more data about CREO stock on TipRanks’ Stock Analysis page.